(Urothelial Carcinoma) Is Gemcitabine Plus Eribulin Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- September 10, 2019
- Reading time: 2 minutes
On August 7, 2019, Sarmad Sadeghi published in the Journal of Clinical Oncology the Phase 2 trial results: "Efficacy and safety of gemcitabine plus eribulin in platinum-ineligible patients with metastatic urothelial carcinoma."
Trial Design
This trial enrolled patients with platinum-ineligible metastatic urothelial carcinoma (defined as creatinine clearance <60 mL/min, or Grade 2 neurotoxicity or hearing impairment). Treatment was gemcitabine 1000 mg/m² + eribulin 1.4 mg/m² on Days 1 and 8 of each 21-day cycle. Primary endpoint: ORR. Secondary endpoints: PFS, OS.
Background: Gemcitabine plus carboplatin and immune checkpoint inhibitors are standard treatments for cisplatin-ineligible metastatic urothelial carcinoma. However, the FDA restricted the use of immune checkpoint inhibitors as first-line therapy in patients with low PD-L1 expression. This trial therefore evaluated gemcitabine plus eribulin in cisplatin-ineligible metastatic urothelial carcinoma.
Patient Characteristics
- Median age: 73 years (range 62–88)
- <70 years: 46% | ≥70 years: 54%
- Sex: Male 17% / Female 83%
- Race: White 92% / Hispanic 4% / Asian 4%
- Disease: Locally advanced 21% / Metastatic 79%
- ECOG performance status: 0 (46%) / 1 (46%) / 2 (8%)
- Baseline eGFR: ≥60 mL/min: 25% / <60 mL/min: 75%
Efficacy Results
- ORR (primary endpoint): 50% (complete response 4%, partial response 46%)
- Median OS: 11.9 months
- Median PFS: 5.3 months
Safety Profile
Most common adverse events: fatigue (83%), neutropenia (79%), anemia (63%), alopecia (50%), AST elevation (50%), constipation (42%), nausea (42%), thrombocytopenia (42%)
Most common Grade 3–4 adverse events: neutropenia (63%), anemia (29%), fatigue (29%)
Conclusions
Based on the Phase 2 trial results, Sarmad Sadeghi concluded that gemcitabine plus eribulin improved ORR, PFS, and OS in platinum-ineligible patients with metastatic urothelial carcinoma.
Source: Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653). J Clin Oncol. 2019 Aug 7.
Tags: #UrothelialCarcinoma
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5